Primary Menu

Education, Events, Publication

Funding & Recognition

Treatment-Contraindicated Complementary and Alternative Medicine in Ovarian Cancer Patients

Semester: Summer 2023


Presentation description

Objective/Background: Complementary and alternative medicine or CAM supplements are taken for various reasons. However, some CAM supplements have poor interactions with chemotherapy, may increase cancer recurrence, and may have a biological effect by influencing metabolic pathways. This project looked specifically at ovarian cancer patients, their self-reported supplements approximately a year prior to diagnosis and up to a year prior to diagnosis, and medical record-abstracted chemotherapy regimens.|Research Question: Are people in the Ovarian Health and Lifestyle Study using supplements that may have bad interactions with their treatment medications?|Methods: 53 Participants diagnosed with invasive epithelial ovarian cancer who received care or consultation at Huntsman Cancer Institute and/or University of Utah, between 21 and 89 years old, U.S. residents, English-speaking, who consented to participate in the Ovarian Health and Lifestyle Study between 2018 to present. |Supplements: Taken from OHLS Questionnaire at time points Baseline past year, Baseline past 3 months, 3 months, 6 months, and 12 months. Based on the scientific literature, contraindicated supplements were categorized into three groups at each time point: antioxidant (Antiox), speed influence on Cytochrome P450 enzymes (CYP Effect), and both Antiox and CYP Effect.|Treatment: All ovarian cancer chemotherapy regimens, including 16 unique medications. Platinum-based therapies and anthracyclines are contraindicated with Antiox supplement regimens. Paclitaxel, doxorubicin, several oral maintenances, and less common chemotherapy medications are contraindicated with CYP Effect supplement regimens. |Results: 9 of 53 participants did not report taking supplements. Almost half (26/53) of our participants reported taking any contraindicated supplement during follow-up. The most common chemotherapy regimen included carboplatin (platinum-based) and paclitaxel which was administered to 47/53 patients.|

Presenter Name: Karina Araujo

Presentation Type: Poster
Presentation Format: In Person
Presentation #53
College: Medicine
School / Department: Population Health Sciences
Research Mentor: Jen Doherty
Date | Time: Thursday, Aug 3rd | 10:30 AM